DD Support Board and Research Team

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Highlights from Omni-Lite's Third Quarter Fiscal 2025 Outstanding Financial Performance Omni-Lite Industries Canada Inc. (TSXV: OML) recently reported its financial results for the third quarter of fiscal 2025, demonstrating notable growth and resilience. With revenue reaching approximately US$4.0 million, Omni-Lite saw a remarkable year-over-year increase of 7.0%...

Understanding the Current UK Housing Market Dynamics The U.K. housing market is currently facing a notable slowdown, primarily driven by tax-related uncertainties associated with fiscal policies. As potential buyers adopt a more cautious stance, residential property transactions have seen a decline. This trend poses immediate risks for sectors linked to housing, including...

Exciting New Driving Experiences at Radford Racing School Recently, Radford Racing School, known as a leader in performance driving education, announced its latest offerings that promise to thrill automotive enthusiasts of all ages and skill levels. With the introduction of six new driving experiences, there's now something for everyone at their legendary racetrack....

AppLovin CEO's Notable Stock Sale Recently, AppLovin Corp (NASDAQ: APP) made headlines with a significant financial event: CEO and Chairperson Arash Adam Foroughi sold over $21.5 million worth of company stock. According to the latest SEC filing, this noteworthy transaction occurred over just two days, with share prices varying from $98.08 to $112.33 during that time....

Olverembatinib Gains Breakthrough Therapy Designation Ascentage Pharma, a prominent global biopharmaceutical company, is making significant strides in the treatment of serious medical conditions. With its latest achievement, olverembatinib has secured a Breakthrough Therapy Designation in China for its use alongside low-intensity chemotherapy in newly-diagnosed patients...